Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?

Papanastasiou, Evangelos, Shergill, Sukhwinder S. (2021) Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? Journal of Psychopharmacology, 35 (9). pp. 1158-1160. ISSN 0269-8811. (doi:10.1177/02698811211000773) (KAR id:96366)

PDF Publisher pdf Language: English This work is licensed under a Creative Commons Attribution 4.0 International License.
Download (184kB) Preview	Preview
This file may not be suitable for users of assistive technology. Request an accessible format
Official URL: https://doi.org/10.1177/02698811211000773

Item Type:	Article
DOI/Identification number:	10.1177/02698811211000773
Subjects:	R Medicine
Divisions:	Divisions > Division of Natural Sciences > Kent and Medway Medical School
Funders:	European Research Council (https://ror.org/0472cxd90)
Depositing User:	Rachael Heller
Date Deposited:	27 Sep 2022 15:07 UTC
Last Modified:	28 Sep 2022 12:32 UTC
Resource URI:	https://kar.kent.ac.uk/id/eprint/96366 (The current URI for this page, for reference purposes)
Shergill, Sukhwinder S.:	https://orcid.org/0000-0003-4928-9100